TransMedics Group announced a 21% increase in Q1 2026 revenue to $173.9 million and net income of $7.3 million, driven by higher use of its Organ Care System and logistics services. Despite increased operating expenses and lower operating margins due to investments in growth and supply chain costs, the company reaffirmed its full-year 2026 revenue guidance of $727 million to $757 million, expecting 20-25% growth. TransMedics is focused on expanding its heart and lung transplant programs in the U.S. and Europe and advancing its kidney transplant technology to drive future growth and improve access to organ transplants globally.

More News (TMDX)

TransMedics shares drop after Q1 margin pressure despite 21% revenue growth

TransMedics reported a 21% revenue increase to $173.9 million in Q1 2026, but its gross margin fell to 58.2%, causing adjusted EPS to drop to $0.30. This margin pressure led to a sell-off in its shares, although the company’s core growth potential re...

Company Fundamentals

Bearish

2 days ago